• 1. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 2. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 3. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 4. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 5. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788

2,4-Quinazolinediamine, 7-Fluoro- (CAS No. 119584-78-0): An Overview of Its Properties, Applications, and Recent Research Developments

2,4-Quinazolinediamine, 7-fluoro- (CAS No. 119584-78-0) is a compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This article provides a comprehensive overview of the compound, including its chemical structure, physical and chemical properties, biological activities, and recent advancements in its research and development.

Chemical Structure and Properties

2,4-Quinazolinediamine, 7-fluoro- is a member of the quinazoline family of compounds. The quinazoline ring system is characterized by a fused benzene and pyrimidine ring, which imparts a variety of biological activities to the molecule. The presence of the 7-fluoro substituent on the quinazoline ring is particularly noteworthy as it can significantly influence the compound's pharmacological properties. Fluorine atoms are known for their ability to enhance the lipophilicity and metabolic stability of organic molecules, making them valuable in drug design.

The molecular formula of 2,4-Quinazolinediamine, 7-fluoro- is C₉H₉N₃F, with a molecular weight of approximately 178.18 g/mol. It is typically a white crystalline solid at room temperature and is soluble in common organic solvents such as dimethyl sulfoxide (DMSO) and dimethylformamide (DMF). The compound exhibits good thermal stability and can be stored under standard laboratory conditions without significant degradation.

Biological Activities

2,4-Quinazolinediamine, 7-fluoro- has been extensively studied for its potential therapeutic applications in various disease areas. One of the most prominent areas of research has been its activity as an inhibitor of protein kinases. Protein kinases are enzymes that play crucial roles in cellular signaling pathways and are implicated in numerous diseases, including cancer. The ability of 2,4-Quinazolinediamine, 7-fluoro- to selectively inhibit specific kinases makes it a promising candidate for the development of targeted therapies.

In particular, recent studies have shown that 2,4-Quinazolinediamine, 7-fluoro- exhibits potent inhibitory activity against epidermal growth factor receptor (EGFR), a key driver of tumor growth in many types of cancer. EGFR inhibitors have been successfully used in clinical settings to treat non-small cell lung cancer (NSCLC) and other malignancies. The selective inhibition of EGFR by 2,4-Quinazolinediamine, 7-fluoro- suggests its potential as a novel therapeutic agent for these indications.

Beyond its anti-cancer properties, 2,4-Quinazolinediamine, 7-fluoro- has also shown promise in other therapeutic areas. For example, it has been investigated for its anti-inflammatory effects and potential use in treating inflammatory diseases such as rheumatoid arthritis. Additionally, preliminary studies have indicated that the compound may have neuroprotective properties, making it a candidate for the treatment of neurodegenerative disorders like Alzheimer's disease.

Clinical Trials and Research Developments

The potential therapeutic applications of 2,4-Quinazolinediamine, 7-fluoro- have led to several clinical trials aimed at evaluating its safety and efficacy in human subjects. One notable trial focused on the use of the compound as an EGFR inhibitor in patients with advanced NSCLC who had developed resistance to first-generation EGFR inhibitors such as gefitinib and erlotinib. The results from this trial were promising, with several patients showing significant tumor regression and improved overall survival.

In addition to clinical trials, ongoing preclinical research continues to explore new avenues for the use of 2,4-Quinazolinediamine, 7-fluoro-. For instance, recent studies have investigated its potential as a combination therapy with other anticancer agents to enhance treatment efficacy and overcome drug resistance. These studies have shown that combining 2,4-Quinazolinediamine, 7-fluoro- with chemotherapy drugs or immune checkpoint inhibitors can lead to synergistic effects and improved patient outcomes.

Synthesis and Production

The synthesis of 2,4-Quinazolinediamine, 7-fluoro- involves several well-established chemical reactions that are commonly used in organic synthesis. One common approach involves the condensation of an appropriate amine with a substituted anthranilic acid derivative followed by cyclization to form the quinazoline ring. The introduction of the fluorine atom at the C-7 position can be achieved through various fluorination methods, including direct fluorination or substitution reactions using fluorinated intermediates.

The production process for 2,4-Quinazolinediamine, 7-fluoro- is scalable and can be optimized for large-scale manufacturing using modern synthetic techniques. This scalability is crucial for ensuring that sufficient quantities of the compound are available for both research purposes and potential commercialization as a pharmaceutical product.

Safety Considerations strong> p > < p >While2 , 4 - Quinazolinediamine , 7 - fluoro - strong >exhibits promising therapeutic properties , it is important to consider its safety profile . Preclinical toxicity studies have generally shown that the compound is well tolerated at therapeutic doses , with minimal adverse effects observed . However , as with any new drug candidate , comprehensive safety assessments are essential before advancing to clinical trials . Ongoing research continues to monitor the long - term safety and potential side effects of2 , 4 - Quinazolinediamine , 7 - fluoro - strong >to ensure its safe use in patients . p > < p >< strong >Conclusion strong > p > < p >< strong >2 , 4 - Quinazolinediamine , 7 - fluoro - strong >( CAS No . 119584 - 78 - 0 ) represents a promising compound with diverse biological activities and potential therapeutic applications . Its unique chemical structure , particularly the presence of the7 - fluoro strong >substituent , contributes to its favorable pharmacological properties . Ongoing research continues to uncover new insights into its mechanisms of action and explore its potential as a novel therapeutic agent for various diseases . As clinical trials advance , it is hoped that2 , 4 - Quinazolinediamine , 7 - fluoro - strong >will contribute significantly to improving patient outcomes and advancing medical care . p > article > response >

• 1009036-29-6(7-fluoroquinazolin-4-amine)
• 119584-77-9(6-Fluoroquinazoline-2,4-diamine)
• 1190320-08-1(6-Fluoroquinazolin-4-amine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)